RBC Capital initiated coverage of Bristol Myers (BMY) with a Sector Perform rating and $60 price target The firm believes Bristol has “large-cap pharma’s most significant Phase 3 path” and sees the recent re-rating of shares reflecting macro factors, valuation, and second half of 2026 catalyst positioning rather than derisking fundamentals, adding that the risk/reward “appears balanced at these levels.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol-Myers Squibb’s New Rheumatoid Arthritis Trial: What Early Pipeline Moves Mean for BMY Investors
- Bristol Myers’ Reblozyl shows positive results in alpha-thalassemia study
- Bristol Myers price target raised to $75 from $66 at Piper Sandler
- BMY’s Mavacamten Safety Extension Wraps Up, Sharpening the Long-Term Outlook in Hypertrophic Cardiomyopathy
- Barclays Bank (BCS) Names Four Pharma Stocks to Buy Now